KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Assets: 2013-2025

Historic Current Assets for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $480.1 million.

  • Xenon Pharmaceuticals' Current Assets fell 27.21% to $480.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $480.1 million, marking a year-over-year decrease of 27.21%. This contributed to the annual value of $635.3 million for FY2024, which is 1.50% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Current Assets of $480.1 million as of Q3 2025, which was down 4.02% from $500.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Current Assets high stood at $794.8 million for Q2 2022, and its period low was $256.3 million during Q3 2021.
  • Over the past 3 years, Xenon Pharmaceuticals' median Current Assets value was $565.5 million (recorded in 2025), while the average stood at $593.6 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Current Assets surged by 207.52% in 2021, and later plummeted by 31.48% in 2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Current Assets (Quarterly) stood at $559.0 million in 2021, then rose by 7.38% to $600.3 million in 2022, then grew by 7.44% to $645.0 million in 2023, then fell by 1.50% to $635.3 million in 2024, then decreased by 27.21% to $480.1 million in 2025.
  • Its Current Assets was $480.1 million in Q3 2025, compared to $500.3 million in Q2 2025 and $565.5 million in Q1 2025.